ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells

N Luo1,2, J Guo1,2, L Chen1,2, W Yang1,2, X Qu1,2 and Z Cheng*1,2

Rho GTPase-activating proteins (RhoGAPs) are implicated in the development and progression of ovarian cancer. ARHGAP10 is a member of RhoGAP proteins and inactivates Cdc42 by converting GTP-bound form to GDP-bound form. Here, we aimed to evaluate ARHGAP10 expression profile and functions in ovarian cancer. The decreased expression of ARHGAP10 was found in 77.3% (58/75) of ovarian cancer tissues, compared with their non-tumorous counterparts. Furthermore, overall survival in ovarian cancer patients with higher expression of ARHGAP10 was longer than those with lower expression. Ectopic expression of ARHGAP10 in two ovarian cancer cell lines with lower expression of ARHGAP10 (A2780 and HO-8910) dramatically suppressed cell proliferation in vitro. In nude mice, its stable overexpression significantly inhibited the tumorigenicity of A2780 cells. We further demonstrated that overexpression of ARHGAP10 significantly inhibited cell adhesion, migration and invasion, resulted in cell arrest in G1 phase of cell cycle and a significant increase of apoptosis. Moreover, ARHGAP10 interacted with Cdc42 and overexpression of ARHGAP10 inhibited the activity of Cdc42 in A2780 cells. Gene set enrichment analysis on The Cancer Genome Atlas dataset showed that KEGG cell cycle, replication and base excision repair (BER) pathways were correlatively with the ARHGAP10 expression, which was further confirmed in ovarian cancer cells by western blotting. Hence, ARHGAP10 may serve as a tumor suppressor through inactivating Cdc42, as well as inhibiting cell cycle, replication and BER pathways. Our data suggest an important role of ARHGAP10 in the molecular etiology of cancer and implicate the potential application of ARHGAP10 in cancer therapy.

Cell Death and Disease (2016) 7, e2157; doi:10.1038/cddis.2015.401; published online 24 March 2016
serous cystadenocarcinoma cohort, https://tcga-data.nci.nih.gov/tcga/) and found that ARHGAP expression was significantly decreased in ovarian tissue compared with the normal tissue from individuals who did not have cancer but were able to donate tissue for other reasons ($P<0.001$). We then detected mRNA levels of ARHGAP10 in 75 pairs of ovarian cancer and adjacent non-tumorous epithelial tissues by quantitative real-time PCR. The log2 (tumor/normal) of each tumor sample was then calculated. Positive log2 (Tumor/Normal) indicated increased expression of ARHGAP10 in tumor tissue while negative log2 indicated reduced expression of ARHGAP10 in tumor tissue. As shown in Figure 1b, ARHGAP10 expression was decreased in 77.3% (58/75) of tested ovarian cancer tissues. Statistical analysis with student’s $t$-test suggested that ARHGAP10 expression was significantly downregulated in ovarian cancer tissues compared with that in noncancerous tissues ($P<0.0001$).

Then, according to the relative ARHGAP10 expression in tumor tissues, the 75 ovarian cancer patients were classified into two groups: relative high group ($n=37$) and relative low group ($n=38$) by using a value of 1.16 (median) as a cutoff. Kaplan–Meier analysis was performed to investigate the correlation of ARHGAP10 expression and prognosis. As shown in Figure 1c, the overall survival time of patients with high ARHGAP10 expression was notably longer than those with low ARHGAP10 expression ($P<0.01$). Our data demonstrated that ARHGAP10 expression was downregulated in ovarian cancer tissues, which was correlated with poor survival of patients with ovarian cancer.

Ectopic overexpression of ARHGAP10 inhibited cell proliferation of ovarian cancer cells in vitro and in vivo. ARHGAP10 expression was then estimated in five ovarian cancer cell lines, OVCAR3, A2780, CAOV3, SKOV3 and HO-8910, by western blotting. Two cell lines, A2780 and HO-8910, showed lower level of ARHGAP10, while the other three cell lines showed higher level (Figure 2a).

To investigate the function of ARHGAP10 in ovarian cancer cells, A2780 and HO-8910 stable pool cells were established by infected with vector control (MOCK) or ARHGAP10 lentivirus and puromycin selection. The ectopic expression of ARHGAP10 in both cells was confirmed by western blotting (Figure 2b).

To determine the effect of ARHGAP10 on cell proliferation, we monitored the proliferation rate of ARHGAP stable expressing cells (A2780/ARHGAP10 and HO-8910/ARHGAP10) for 3 days by CCK-8 assay. We observed that A2780/ARHGAP10 and HO-8910/ARHGAP10 cells exhibited a significantly slower growing phenotype than corresponding control cells (MOCK, Figure 2c). These results indicated that ARHGAP10 exerts growth-inhibitory effects on ovarian cancer cells.

To determine the effect of ARHGAP10 on tumorigenicity in vivo, equal number of A2780 stably expressed vector (MOCK) or ARHGAP10 was injected subcutaneously into nude mice and tumor formation was examined for 36 days. As shown in Figure 2d, although both cells were able to form tumors, the tumor growth rate of nude mice injected with ARHGAP10-overexpressed cells was significantly more slowly than that of mice injected with control cells. The volume and weight of ARHGAP10-overexpressed tumors was less than 35% that of control tumors at 36 days when the nude mice were killed.

ARHGAP10 overexpression induced G1 phase arrest and cell apoptosis. Then we assessed whether ARHGAP10 affects the cell cycle of ovarian cancer cells by propidium iodide (PI) staining and flow cytometry analysis. As shown in Figure 3a, compared with MOCK cells, ARHGAP10 overexpression led to a significant increase of G0/G1 phase cells (increased ratio: A2780, 28.4%; HO-8910, 36.2%).

We then explored the effects of ARHGAP10 on cell apoptosis by Annexin V-fluorescein isothiocyanate/PI staining assay. As shown in Figure 3b, a notable increase of cell apoptosis was noted in ARHGAP10-overexpressed A2780 and HO-8910 cells as compared with MOCK cells. These data suggested that increased expression of ARHGAP10 notably induced G0/G1 phase cell cycle arrest and cell apoptosis of...
Figure 2  Knockdown ARHGAP10 inhibited ovarian cancer cells proliferation in vitro and in vivo. (a) Expression of ARHGAP10 in five ovarian cancer cell lines as determined by western blotting. Left panel, representative results of western blot; right panel, protein levels relative to GAPDH. (b) Ectopic expression of ARHGAP10 in A2780 and HO-8910 cells was detected by western blotting. (c) Ectopic expression of ARHGAP10 significantly reduced cell proliferation as determined by CCK-8 assay. (d) A2780 cells stably infected with vector or ARHGAP10 virus were subcutaneously inoculated into nude mice (six per group). Overexpression of ARHGAP10 significantly inhibited tumor growth in nude mice xenograft model (\(^{**}P<0.01, \;***P<0.001\))
ovarian cancer cells, which may cause the inhibition of cell proliferation.

ARHGAP10 overexpression inhibited the adhesion, motility and invasiveness of ovarian cancer cells. Tumor cells are often characterized by the reduction in cell–cell and/or cell–matrix adhesion, which correlates with tumor invasion and metastasis. Then, we investigated whether ARHGAP10 affected the adherent, migrated and invasive ability of ovarian cancer cells by fibronectin-adhesion assay and

Figure 3 ARHGAP10 overexpression induced cell arrest in G1 phase of cell cycle (a) and a dramatic increase of apoptosis (b). Data were based on at least three independent experiments, and shown as mean ± S.D. (**P < 0.001)
Transwell assay, respectively. As shown in Figure 4, ARHGAP10-overexpressed cells have lower adherent ability than MOCK cells (Figure 4a). ARHGAP10 overexpression caused a significant reduction in cell migration, with only 52.9% and 39.5% cells migrating in A2780 and HO-8910 cells, respectively (Figure 4b). ARHGAP10-overexpressed cells showed significant reduced invasive ability compared with control cells. The number of invaded cells was 33.3% and 39.5% of that of the control cells in A2780 and HO-8910 cells, respectively (Figure 4c). These data suggested an inhibitory role of ARHGAP10 on ovarian cancer metastasis.

**ARHGAP10 inhibited the activation of Cdc42.** ARHGAP10 has been shown to be a potent GAP for Cdc42.8 We then tried to detect their interaction by co-immunoprecipitation experiments in A2780 cells. As shown in Figure 5a, the endogenous Cdc42 co-immunoprecipitated with ARHGAP10, but this did not occur with the control IgG. Moreover, GST-PAK1-binding domain pull-down assay was carried out to test Cdc42 activity followed by western analysis with an anti-Cdc42 antibody. As shown in Figure 5b, ectopic expression of ARHGAP10 notably inhibited the activity of Cdc42, while Cdc42 expression was not affected by ARHGAP10. Cdc42 has been implicated in the promotion of tumorigenesis.19 We then suppressed its expression in A2780 cells (Figure 5c) and found that Cdc42 knockdown significantly suppressed the proliferation, cell cycle progression, adhesion, motility and invasiveness of A2780 cells.
Figure 5  ARHGAP10 functions through inhibiting Cdc42 activation. (a) Co-immunoprecipitation analysis showed that ARHGAP10 interacts with Cdc42 in A2780 cells. (b) Activation of Cdc42 was determined by GST-PBD pull-down assay. GST-PBD fusion protein was used as quantitative control, and total Cdc42 in protein lysates was shown. (c) Cdc42 expression was detected in A2780 cells transfected with Cdc42 siRNA or control siRNA (Mock) by western blotting. (d) Cdc42 knockdown significantly reduced cell proliferation as determined by CCK-8 assay. (e) Cdc42 knockdown induced cell arrest in G1 phase of cell cycle. (f) Cdc42 knockdown notably inhibited the adhesion, motility and invasiveness of A2780 cells (**P<0.01, ***P<0.001)
These data suggested that ARHGAP10 may exert its function in ovarian cancer through suppressing Cdc42 activity.

**ARHGAP10-associated pathways in ovarian cancer.** To further probe the ARHGAP10-associated pathways on an unbiased basis, we performed Gene Set Enrichment Analysis (GSEA) using data of the OV cohort from TCGA (568 patients). GSEA is designed to detect coordinated differences in expression of predefined sets of functionally related genes. The KEGG cell cycle, DNA replication and base excision repair (BER) pathways were identified with the significant association with ARHGAP10 expression in the TCGA dataset (Figure 6a-c).
To validate the GSEA results, we then detected the expression of cell cycle (PCNA and PLK1), DNA replication (MCM2 and MCM3) and BER pathways-related proteins (PARP1 and PARP2) in ovarian cancer cells transiently overexpressed ARHGAP10. The levels of detected protein were significantly decreased in both A2780 and HO-8910 cells (Figure 6d) after the overexpression of ARHGAP10.

Discussion

ARHGAP10 belongs to RhoGAP proteins, which negatively regulate Rho GTPases. The roles of RhoGAP proteins have been investigated in cancer development and progression.21-25 Involvement of ARHGAP10 in cancers has also been recently concerned.4,14,15 In the present study, we confirmed that ARHGAP10 was extremely downregulated in 75 ovarian cancer tissues, compared with paired normal tissues. Importantly, the overall survival of patients with lower ARHGAP10 expression levels was shorter than that with higher expression. These findings indicate that ARHGAP10 may be considered as a novel prognostic marker for ovarian cancer.

To further investigate the functions of ARHGAP10 in ovarian cancer, we explored the effects of ARHGAP10 overexpression on the cell behavior of ovarian cancer cells. Ectopic expression of ARHGAP10 in two ovarian cancer cell lines resulted in a significant inhibition in cell proliferation (Figure 2), adhesion, migration and invasion (Figure 4), and a remarkable induction of ARHGAP10 overexpression (Figure 2d). While, downregulation of ARHGAP10 expression by siRNA transfection in higher expression OVCAR3 cells induced cell proliferation, adhesion, migration and invasion (Supplementary Figure S1). Our data indicate that ARHGAP10 may act as a tumor suppressor in ovarian cancer.

Further, we tried to explore the mechanisms by which ARHGAP10 exerts its function. GSEA indicated that ARHGAP10 expression was associated with the KEGG cell cycle, DNA replication and BER pathway (Figure 5). Cell cycle and DNA replication regulation are frequently abnormal in most common malignancies, resulting in aberrant cell proliferation.26 Cancer occurs primarily in proliferative tissues. When DNA damage in proliferating cells are not repaired because of inadequate expression of a DNA repair gene, the risk of cancer is increased.27 Here, ARHGAP10 overexpression remarkably decreased cell cycle (PCNA and PLK1), DNA replication (MCM2 and MCM3) and BER pathway (PARP1 and PARP2)-related factors, which may account for its suppression effects on the tumorigenicity of ovarian cancer. Furthermore, Dubois et al.3 has demonstrated that ARHGAP10 functions as a potential GAP for Cdc42 in vitro. Previous studies have demonstrated a role for Cdc42 in promoting cell cycle progression.38-40 Here, we confirmed that ARHGAP10 can bind with Cdc42 (Figure 5a), thus inhibiting Cdc42 activity (Figure 5b). We also found that Cdc42 knockout significantly inhibited cell proliferation (Figure 5c) and cell cycle progression (Figure 5d). These data suggested that ARHGAP10 might have a pivotal role in regulation of the cell cycle and DNA replication signal pathways through inhibited Cdc42 activation. Further investigations are required to understand the exact mechanisms by which ARHGAP10 regulates these pathways.

In conclusion, our study suggests that ARHGAP10 acts as a tumor suppressor in ovarian cancer cell line, and the downregulation of ARHGAP10 expression is closely associated with the poor prognosis of ovarian cancer. Whether ARHGAP10 can be used as a potential therapeutic target for ovarian cancer remains to be further investigated.

Materials and Methods

Patients and tissue samples. Ovarian cancer tissues and paired adjacent nontumorous epithelial tissues were collected from 75 patients diagnosed with Stage I/III epithelial ovarian serous adenocarcinoma, who were admitted to Gynecology & Obstetrics, Yangpu Hospital, Tongji University (Shanghai, China) between 2006 and 2009. Tissue samples were immediately frozen in liquid nitrogen and kept at −80 °C until used. The study was approved by Ethics Committee of Tongji University and written informed consent was obtained from all patients. All patients have complete clinical and pathological follow-up data. Overall survival was defined as the interval between the dates of surgery and death.

RNA isolation and quantitative RT-PCR. Total RNA was extracted from tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The mRNA levels of ARHGAP10 were determined by quantitative RT-PCR using the SYBR Green (Thermo Fisher Scientific, Rockford, IL, USA) on ABI 7300 instrument (Applied Biosystems, Foster City, CA, USA), with GAPDH as an internal control. The primers are as follows: ARHGAP10 (NM_024605.3), 5'-ACTGAAACCCGTGATAAACCC-3' and 5'-ATCTGCTCTTGTA AARTG-3'; GAPDH (NM_001256799.1), 5'-CACCACTCTCCACACTTTT-3' and 5'-CCACACCTTGTTGCTTAG-3'. All reactions were conducted using the following cycling parameters, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 45 s. Verification of specific product amplification was determined by dissociation curve analysis. Comparative Ct method was used for quantification of the transcripts. The fold-change for target genes normalized by internal control was determined by the formula 2^-△△CT. All data represent the average of three replicates.

Cell culture, transfection, lentiviral infection and RNA interference. Five human ovarian cancer cell lines (OVCAR3, A2780, CAOV3, SKOV3 and HO-8910) were obtained from Chinese Type Culture Collection, Chinese Academy of Sciences and maintained at 37 °C in a humidified air atmosphere containing 5% CO2. All culture medium (Life Technologies, Foster City, CA, USA) was supplemented with 10% fetal bovine serum, 100 Unit penicillin sodium and 100 mg/ml streptomycin sulfate. OVCAR3, A2780 and HO-8910 cells were cultured in RPMI 1640, CAOV3, SKOV3 and HEK 293 T cells were cultured in DMEM. Lentiviral constructs of CD513B-1 empty vector (System Biosciences, Mountain View, CA, USA) or CD513B-1-ARHGAP10 were cotransfected with viral packaging plasmids (psPAX2 and pMD2.G) into HEK293T cells by using lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Viral supernatant was harvested after 48 h and filtered through 0.45-μm filter. A2780 cells and HO-8910 cells were infected with ARHGAP10 lentivirus or control lentivirus in the presence of 8 μg/ml Polybrene. Stable pools were obtained in the presence of 0.5 μg/ml puromycin (Sigma, St. Louis, MO, USA) and used for following assays.

siRNA specific targeting human Cdc42 (GGAGCAGAUUGAUUCCCAUAU) and negative control siRNA were synthesized by Genepharma Co., Ltd (Shanghai, China). siRNA transfection was performed on A2780 cells using Lipofectamine2000 (Invitrogen).

Antibodies and western blotting. Primary antibodies were obtained from the following companies: (i) ARHGAP10 and Cdc42, Santa Cruz Biotech (Santa Cruz, CA, USA); (ii) GAPDH, CST Biotech (Danvers, MA, USA); (iii) PCNA, PLK1, MCM2, MCM3, PARP1 and PARP2, Abcam (Cambridge, MA, USA). Horseradish peroxidase-conjugated goat anti-mouse secondary antibody or goat anti-rabbit secondary antibody was purchased from Beyotime (Shanghai, China).

Cells were lysed in ice-cold radioimmunoprecipitation assay buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 0.5% Na-deoxycholate) containing protease inhibitors. Protein concentration was measured by BCA protein...
Stable pool cells were seeded into fibronectin pre-experiments were performed in triplicate. The percentage of cells in the G0/G1, S, and G2/M phases was determined by the ribonuclease staining kits (Multisciences, Hangzhou, China), DNA content was harvested and fixed with 70% ethanol at 37 °C for 1 h. After non-adherent cells were washed off with PBS, attached cells were fixed in 4% paraformaldehyde for 10 min and stained with GIEMSA solution. The resulting beads were resuspended in Laemmli sample buffer and analyzed by western blotting.

In vivo tumorigenicity assay. The animal study was carried out in accordance with the guidelines approved by the Animal Experimentation Ethics Committee of Yangpu Hospital, Tongji University. Athymic Balb/c nude mice (aged 5 weeks) were provided by Siac Laboratory Animal Co. Ltd. (Shanghai, China). The mice were housed in a pathogen-free animal facility and randomly assigned to the control or experimental group (six mice per group). A2780 stable cells were harvested and injected intraperitoneally into the flank of each mouse (2 x 10^6 cells/0.1 ml). Tumor volume was estimated every 3 days using the following formula: volume = 1/2 x length x width^2. All mice were killed after 36 days.

Evaluation of cell cycle distribution and cell apoptosis by flow cytometry. PI staining was used to analyze DNA content. Stable pool cells were harvested and fixed with 70% ethanol at −20 °C overnight. After treatment with PI/ribonuclease staining kits (Multisciences, Hangzhou, China), DNA content was analyzed on a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The percentage of cells in the G0/G1, S, and G2/M phases was determined by the FlowJo cell cycle analysis program (Tree Star, San Carlos, CA, USA).

The percentage of cells actively undergoing apoptosis was determined by double staining with Annexin V-fluorescein isothiocyanate and PI. Stable pool cells were harvested, double-labeled with Annexin V-fluorescein isothiocyanate and PI apoptosis detection kits (KeyGEN Biotech, Nanjing, China), and analyzed using a FACScan flow cytometer. At least 20,000 cells were acquired for each sample. The experiments were performed in triplicate.

Cell adhesion assay. Stable pool cells were seeded into fibronectin pre-coated 12-well plates at a density of 1 x 10^5 cells per well and allowed to adhere for 37 °C for 2 h. After non-adherent cells were washed off with PBS, attached cells were fixed in 4% paraformaldehyde for 10 min and stained with GIEMSA solution. The adherent cells were counted and imaged under the microscope using an Olympus inverted microscope (Lake Success, NY, USA).

Transwell assay. To determine cell migration, stable pool cells were plated in medium without serum in the top chamber of a transwell (Corning, Corning, NY, USA). The bottom chamber contained standard medium with 10% fetal bovine serum. After 24-h incubation, the cells that had migrated to the lower surface of the membrane were fixed with formalin, stained with 0.05% crystal violet, counted and imaged under the microscope. Experiments were carried out at least three times. Cell invasion assay was performed in a Matrigel-coated Transwell and other procedure was the same as described above.

Gene set enrichment analysis (GSEA). GSEA is a method of analyzing and interpreting microarray and such data using biological knowledge. In this study, ovarian serous cystadenocarcinoma cohort was obtained from TCGA (https://tcga-data.nci.nih.gov/tcga/) and analyzed by GSEA as previously described. GSEA firstly generated an ordered list of all genes according to their correlation with ARHGAP10 expression, and then a predefined gene set receives an enrichment score, which is a measure of statistical evidence rejecting the null hypothesis that its members are randomly distributed in the ordered list. The expression level of ARHGAP10 gene was used as phenotype label, and 'Metric for ranking genes' was set to Pearson Correlation.

Statistical analysis. Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software). Data were presented as the mean ± standard deviation (S.D.). The data were analyzed using the two-tailed Student's t-test to calculate the statistical significance of difference between groups. Kaplan–Meier method and log-rank test were performed for patients' survival analyses. Statistically significant differences were defined as having a P < 0.05.

Conflict of Interest
The authors declare no conflict of interest.
20. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007; 23: 3251–3253.

21. Wang J, Qian J, Hu Y, Kong X, Chen H, Shi Q et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun 2014; 5: 4735.

22. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Diagn Pathol 2008; 3: 203.

23. Durkin ME, Ullmannova V, Guan M, Popescu NC.Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 2007; 26: 4580–4589.

24. Gen Y, Yasui K, Zen K, Nakajima T, Tsuji K, Endo M et al. Polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2005; 68: 126–133.

25. Wong C-M, Yam JW-P, Ching Y-P, Yau T-O, Leung TH-Y, Jin D-Y et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148–152.

26. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–348.

27. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2006; 442: 33–41.

28. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of polo-like kinase 1 (PLK1) in colorectal cancer. Int J Oncol 2007; 30: 617–625.

29. Lee KE, Lee H-J, Kim YH, Yu HJ, Yang H-K, Kim W-H et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2005; 70: 126–133.

30. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148–152.

31. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148–152.

32. Ramnath N, Hernandez FJ, Tan D-F, Huberman JA, Natarajan N, Beck AF et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001; 19: 4259–4266.

33. Yang J, Ramnath N, Moyaich KB, Asch HL, Swede H, Ahram SJ et al. Prognostic significance of MCM2, Ki-67 and gelisol in non-small cell lung cancer. BMC Cancer 2006; 6: 203.

34. Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlin M, Jirstrom K. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RRM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol 2012; 7: 1746–1756.

35. Gan N, Du Y, Zhang W, Zhou J. Increase of Mcm3 and Mcm4 expression in cervical squamous cell carcinomas. Eur J Gynaecol Oncol 2010; 31: 291.

36. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8: 363–369.

37. Yelamos J, Fares J, Liscianna L, Ampurdanes C, Martin-Caballero J. PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res 2011; 1: 328.

38. Bourdoulous S, Orend G, MacKenna DA, Pasqualini R, Ruoslahti E. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J Cell Biol 1998; 143: 267–276.

39. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093–2101.

40. Yau H, Zhang H, Wu X, Zhang Z, Du D, Zhou W et al. Hepatocyte-specific deletion of Cdc42 results in delayed liver regeneration after partial hepatectomy in mice. Hepatology 2009; 49: 240–249.

41. Zhang YH, Wang Y, Yaozlai AH, Ashby F, Zhang D, Yin ZF et al. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med 2014; 12: 483–494.

42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.

43. Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J et al. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget 2014; 5: 2230–2242.

44. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014; 25: 668–681.

45. Sun T, Du W, Xiong H, Yu Y, Weng Y, Ren L et al. TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. Clin Cancer Res 2014; 20: 4689–4704.